Company Overview and News

5
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of May 14

2018-05-13 seekingalpha
After an extremely busy week last week, there are only two Canadian Dividend All-Stars scheduled to report earnings this coming week. Unfortunately, neither are expected to increase dividends. However, we have plenty to catch up on from last week before banks start to report in two weeks.
FINGF FNV.WT.A LSDAF FNV KEYUF OTEX CIFAF FTT T LAS.A WN AQN OTC ONEXF KEY CIX TU FNV

0
Finning Reports on Voting Results from its Annual Meeting of Shareholders

2018-05-11 globenewswire
VANCOUVER, British Columbia, May 11, 2018 (GLOBE NEWSWIRE) -- Finning International Inc. (TSX:FTT) announces the voting results from its Annual Meeting of Shareholders held on Wednesday, May 09, 2018 in Vancouver, British Columbia.
FINGF FTT

49
Finning Announces Renewal of Share Repurchase Program

2018-05-07 globenewswire
VANCOUVER, British Columbia, May 07, 2018 (GLOBE NEWSWIRE) -- Finning International Inc. (TSX:FTT) ("Finning") announced today that it has received approval from the Toronto Stock Exchange ("TSX") to renew its normal course issuer bid (“NCIB”) to purchase for cancellation up to 3,000,000 of its common shares, representing approximately 1.8% of the total common shares issued and outstanding of 168,402,412 common shares as at April 23, 2018.
FINGF CATR CAT FTT

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

20h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

20h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:FTT / Finning Intl on message board site Silicon Investor.

Verizon FiOS FTTP Discussion Board FTTH/FTTx/Metro Fiber